Key result
Among 79 Mexican children treated with anthracyclines, 39.2% carried the protective SLC28A3 variant, which was associated with a clinically important decrease of fractional shortening.
Why the study?
To evaluate the association between genetic risk variants in SLC28A3, RARG, and UGT1A6 and anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Are genetic variants in SLC28A3, RARG, and UGT1A6 associated with anthracycline-induced cardiotoxicity in Mexican pediatric patients?
Cohort (n=79)
Are genetic variants in SLC28A3, RARG, and UGT1A6 associated with anthracycline-induced cardiotoxicity in Mexican pediatric patients?
In Mexican pediatric patients treated with anthracyclines, the SLC28A3-rs7853758 variant is relatively common and associated with changes in fractional shortening.
May inform ancestry-specific screening in Mexican children; leaves open predictive utility for anthracycline cardiotoxicity.
Background: The aim of this study was to evaluate the association between well-defined genetic risk variants in SLC28A3, RARG and UGT1A6 and anthracycline-induced cardiotoxicity in Mexican pediatric patients. Methods: We tested a cohort of 79 children treated with anthracyclines for the presence of SLC28A3-rs7853758, RARG-rs2229774 and UGT1A6-rs17863783. Results: The SLC28A3-rs7853758 variant was more frequent in this cohort, while the UGT1A6-rs17863783 and RARG-rs2229774 variants were present at lower frequencies. A clinically important decrease of fractional shortening was associated with SLC28A3-rs7853758 variant. Conclusion: In this cohort, 39.2% of patients carried the protective SLC28A3 variant. A small number of tested patients have the risk variants of UGT1A6 and RARG. None of the patients shared the two risk variants.
No takes yet. Share an insight, caveat, or question.
Vargas-Neri et al. (2022) conducted a cohort in Anthracycline-induced cardiotoxicity (n=79). Genetic variants in SLC28A3, RARG and UGT1A6 was evaluated on Anthracycline-induced cardiotoxicity (decrease of fractional shortening). Among 79 Mexican children treated with anthracyclines, 39.2% carried the protective SLC28A3 variant, which was associated with a clinically important decrease of fractional shortening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: